Literature DB >> 22105225

Design and synthesis of dual-ligand modified chitosan as a liver targeting vector.

Houxiang Chen1, Min Li, Tao Wan, Qichang Zheng, Mingrong Cheng, Shiqi Huang, Yong Wang.   

Abstract

Vector plays an important role in hepatic targeted drug delivery system. In this study, a novel material as a liver targeting vector, dual-ligand modified chitosan (GCGA) composed of chitosan (CTS), glycyrrhetinic acid (GA) and lactobionic acid (LA), was designed and synthesized by an orthogonal experiment with two-step synthesis under mild conditions. The synthesized final product was characterized and confirmed by FTIR and (1)H-NMR spectroscopy, and DS of GA and LA in CTS were measured to be 13.77 and 16.74 mol% using (1)H-NMR, respectively. The cytotoxicity of CTS and GCGA was concentration dependent which was inverse proportion to the cell viability by MTT assay using L929 cell line, and inhibitory concentration 50% (IC50) was 0.2 mg/ml for GCGA. The in vitro targeting efficiency and the in vitro cellular uptake were investigated. Compared with CTS NPs and GA-CTS NPs, GCGA NPs showed good cell specificity to BEL-7402 cells via the dual-ligand-receptor-mediated recognition, leading to a higher affinity to BEL-7402 cells. The results suggested that GCGA described here has the potential to be used as an effective vector for hepatic targeted drug therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22105225     DOI: 10.1007/s10856-011-4494-1

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  28 in total

Review 1.  Liver gene therapy: advances and hurdles.

Authors:  T H Nguyen; N Ferry
Journal:  Gene Ther       Date:  2004-10       Impact factor: 5.250

Review 2.  Recent advances on chitosan-based micro- and nanoparticles in drug delivery.

Authors:  Sunil A Agnihotri; Nadagouda N Mallikarjuna; Tejraj M Aminabhavi
Journal:  J Control Release       Date:  2004-11-05       Impact factor: 9.776

3.  Structural features and bioactivities of the chitosan.

Authors:  Gang Chen; Jie Mi; Xiaohou Wu; ChunLi Luo; JiaBing Li; YaXiong Tang; Jie Li
Journal:  Int J Biol Macromol       Date:  2011-06-15       Impact factor: 6.953

4.  Specific binding of glycyrrhetinic acid to the rat liver membrane.

Authors:  M Negishi; A Irie; N Nagata; A Ichikawa
Journal:  Biochim Biophys Acta       Date:  1991-07-01

5.  Synthesis and efficient hepatocyte targeting of galactosylated chitosan as a gene carrier in vitro and in vivo.

Authors:  Mingrong Cheng; Qing Li; Tao Wan; Xiaowu Hong; Houxiang Chen; Bing He; Zhijian Cheng; Hongzhi Xu; Tao Ye; Bingbing Zha; Jingbo Wu; Runjiao Zhou
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2011-06-07       Impact factor: 3.368

6.  Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.

Authors:  Qin Tian; Chuang-Nian Zhang; Xiu-Hua Wang; Wei Wang; Wei Huang; Rui-Tao Cha; Chun-Hong Wang; Zhi Yuan; Min Liu; Hai-Ying Wan; Hua Tang
Journal:  Biomaterials       Date:  2010-03-19       Impact factor: 12.479

7.  Inhibition of protein kinase C by the 12-O-tetradecanoylphorbol-13-acetate antagonist glycyrrhetic acid.

Authors:  C A O'Brian; N E Ward; V G Vogel
Journal:  Cancer Lett       Date:  1990-01       Impact factor: 8.679

8.  Arabinogalactan for hepatic drug delivery.

Authors:  E V Groman; P M Enriquez; C Jung; L Josephson
Journal:  Bioconjug Chem       Date:  1994 Nov-Dec       Impact factor: 4.774

9.  Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte.

Authors:  A L Schwartz; D Rup; H F Lodish
Journal:  J Biol Chem       Date:  1980-10-10       Impact factor: 5.157

10.  Semiquantitative study of the EDC/NHS activation of acid terminal groups at modified porous silicon surfaces.

Authors:  S Sam; L Touahir; J Salvador Andresa; P Allongue; J-N Chazalviel; A C Gouget-Laemmel; C Henry de Villeneuve; A Moraillon; F Ozanam; N Gabouze; S Djebbar
Journal:  Langmuir       Date:  2010-01-19       Impact factor: 3.882

View more
  8 in total

1.  Dual-Ligand Functionalized Core-Shell Chitosan-Based Nanocarrier for Hepatocellular Carcinoma-Targeted Drug Delivery.

Authors:  Amr Hefnawy; Islam H Khalil; Kholoud Arafa; Marwan Emara; Ibrahim M El-Sherbiny
Journal:  Int J Nanomedicine       Date:  2020-02-05

Review 2.  Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.

Authors:  Min Li; Weiyue Zhang; Birong Wang; Yang Gao; Zifang Song; Qi Chang Zheng
Journal:  Int J Nanomedicine       Date:  2016-10-31

3.  Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA.

Authors:  Qi Chang Zheng; Shuai Jiang; Yu Zhe Wu; Dan Shang; Yong Zhang; Shao Bo Hu; Xiang Cheng; Chen Zhang; Ping Sun; Yang Gao; Zi Fang Song; Min Li
Journal:  Front Bioeng Biotechnol       Date:  2020-06-10

4.  Recent Advances in miRNA Delivery Systems.

Authors:  Ishani Dasgupta; Anushila Chatterjee
Journal:  Methods Protoc       Date:  2021-01-20

5.  Dual-ligated metal organic framework as novel multifunctional nanovehicle for targeted drug delivery for hepatic cancer treatment.

Authors:  Mostafa Fytory; Kholoud K Arafa; Waleed M A El Rouby; Ahmed A Farghali; Mahmoud Abdel-Hafiez; Ibrahim M El-Sherbiny
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

6.  CTL-doxorubicin (DOX)-gold complex nanoparticles (DOX-AuGCs): from synthesis to enhancement of therapeutic effect on liver cancer model.

Authors:  Qiqian Liu; Hui Liu; Pasquale Sacco; Nadia Djaker; Marc Lamy de la Chapelle; Eleonora Marsich; Xiaowu Li; Jolanda Spadavecchia
Journal:  Nanoscale Adv       Date:  2020-09-29

7.  Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo.

Authors:  Mingrong Cheng; Xiaoyan Gao; Yong Wang; Houxiang Chen; Bing He; Yingchun Li; Jiang Han; Zhiping Zhang
Journal:  Int J Nanomedicine       Date:  2013-11-06

8.  Doxorubicin‑loaded dual‑functional hyaluronic acid nanoparticles: Preparation, characterization and antitumor efficacy in vitro and in vivo.

Authors:  Guixiang Tian; Xiue Sun; Jingkun Bai; Jinhua Dong; Bo Zhang; Zhiqin Gao; Jingliang Wu
Journal:  Mol Med Rep       Date:  2018-11-22       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.